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Abstract
Background—Ensuring appropriate cancer screenings among low-income persons with chronic 
conditions and persons residing in long-term care (LTC) facilities presents special challenges. This 
study examines the impact of having chronic diseases and of LTC residency status on cancer 
screening among adults enrolled in Medicaid, a joint state-federal government program providing 
health insurance for certain low-income individuals in the U.S.
Methods—We used 2000–2003 Medicaid data for Medicaid-only beneficiaries and merged 2003 
Medicare-Medicaid data for dually-eligible beneficiaries from four states to estimate the 
likelihood of cancer screening tests during a 12-month period. Multivariate regression models 
assessed the association of chronic conditions and LTC residency status with each type of cancer 
screening.
Results—LTC residency was associated with significant reductions in screening tests for both 
Medicaid-only and Medicare-Medicaid enrollees; particularly large reductions were observed for 
receipt of mammograms. Enrollees with multiple chronic comorbidities were more likely to 
receive colorectal and prostate cancer screenings and less likely to receive Papanicolaou (Pap) 
tests than were those without chronic conditions.
Conclusions—LTC residents have substantial risks of not receiving cancer screening tests. Not 
performing appropriate screenings may increase the risk of delayed/missed diagnoses and could 
increase disparities; however, it is also important to consider recommendations to appropriately 
discontinue screening and decrease the risk of overdiagnosis. Although anecdotal reports suggest 
that patients with serious comorbidities may not receive regular cancer screening, we found that 
having chronic conditions increases the likelihood of certain screening tests. More work is needed 
to better understand these issues and to facilitate referrals for appropriate cancer screenings.
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INTRODUCTION
Ensuring appropriate receipt of cancer screens among low-income persons with chronic 
medical conditions and persons residing in long-term care (LTC) facilities presents special 
challenges. These populations may be at risk of both too few and too many screenings. For 
cancer screening, “overdiagnosis” refers to the detection of tumors that would have not 
developed into symptomatic disease during the screened individuals’ lifetimes [1]. This may 
result from continued cancer screening among individuals older than recommended ages. In 
contrast, underscreening reflects inadequate testing for cancer among individuals who could 
potentially benefit from early diagnosis. Previous reports have indicated that individuals 
with comorbidities are less likely to receive cancer screenings [2–4]. For individuals with 
chronic conditions, health care providers may focus on the most severe problems and may 
not address preventive care needs [5].
Health care providers treating patients in LTC environments may also be more likely to 
focus on day-to-day issues than on recommended cancer screenings. In surveys using 
hypothetical clinical case vignettes, physicians were significantly less likely to recommend 
mammography for women residing in nursing homes compared with those residing at home 
[6,7]. Although cancer screening may not be appropriate for some LTC residents based on 
remaining life expectancy, the expected benefit of early detection may be sufficiently large 
among other residents to justify routine screening.
Medicaid, a joint state-federal government program providing health insurance for certain 
low-income individuals in the U.S., pays for medical care for a substantial proportion of the 
U.S. population. Individuals enrolled in Medicaid, compared with those having private 
insurance, receive less cancer screening and thus are already potentially at risk for delayed 
cancer diagnosis [8]. For this study, we analyzed claims data from Medicaid enrollees to 
assess the association of chronic conditions and LTC residence with receipt of cancer 
screening services.
METHODS
Data Sources
For this study, we used Medicaid Analytic eXtract (MAX) data for four states: Georgia, 
Illinois, Louisiana, and Maine. MAX is a uniform Medicaid enrollment, utilization, and 
payment dataset created by the Centers for Medicare & Medicaid Services (CMS) [9]. Both 
individuals with Medicaid coverage only and dually-eligible Medicaid-Medicare enrollees 
were included in the study populations. Analyses of the Medicaid-only population used 
2000–2003 MAX data, which were the most current years available when the study began. 
Analyses of the dual-eligible Medicare-Medicaid population used 2003 MAX data merged 
with 2003 Medicare claims and enrollment data. The study protocol was approved by RTI 
International’s Institutional Review Board and the CMS Privacy Review Board.
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Study Population
The study population included adult Medicaid beneficiaries in the four study states who 
were age- and sex-eligible for the cancer screening tests. Only Medicaid enrollees in fee-for-
service programs were included in the study population; those in Medicaid managed-care 
programs were excluded due to incomplete claims data. Dually-eligible enrollees were 
identified using MAX variables that indicate the presence of Medicare claims, enrollment, or 
eligibility records for a Medicaid enrollee. The age- and sex-eligibility requirements for the 
cancer screening tests used in this study were:
• Mammography: female, age 40 and older;
• Papanicolaou (Pap) test: female, age 21 and older;
• Colorectal cancer (CRC) screening: age 50 and older; and
• Prostate cancer screening: male, age 50 and older.
Each observation in the analysis represented a period of up to 12 months of Medicaid 
coverage. For dually-eligible beneficiaries, the observation corresponded to the calendar 
year 2003. Medicaid-only beneficiaries, for whom we had up to four years of data, could 
have multiple observations in the study data beginning with the first month of fee-for-service 
Medicaid enrollment in the data and continuing for up to 12 months. Use of 12 month 
observation periods decreases the likelihood that observed rates of cancer screening will be 
biased by differential length of Medicaid enrollment. It is important to note that these 
analyses examined the likelihood of receiving each type of cancer screening in an 
observation period, and did not assess concordance with guideline-recommended screening 
practices.
We excluded an observation if any of the following were true during the 12-month period:
• the beneficiary was pregnant, observations excluded=578,078;
• the beneficiary had cancer, observations excluded=141,025; or
• the beneficiary had less than 4 months of fee-for-service enrollment, 
observations excluded=531,027.
We included part-year enrollees (with at least 4 months of enrollment) because they are a 
significant portion of the Medicaid population; excluding them could bias estimates if they 
differ systematically from full-year enrollees. Among dually-eligible beneficiaries and 
Medicaid-only beneficiaries included in our analyses, 21.1% and 37.3% (respectively) had 
less than 12 months of enrollment during an observation period.
This study population (Medicaid enrollees eligible to receive cancer screenings) was 
classified based on LTC residency status (yes/no) and number of serious comorbidities (0, 1, 
2–3 or 4+). If an individual was eligible for a particular screening test, he/she was included 
in analyses of both LTC status and comorbidities.
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Study Variables
The dependent variable in analyses indicated whether a beneficiary received an indicated 
cancer screening test during an observation period, based on having at least one claim with a 
procedure code for that test during the observation period. An individual was considered to 
have received CRC screening if they had a claim for barium enema, colonoscopy, flexible 
sigmoidoscopy, or fecal occult blood test (FOBT). An individual with a claim for either 
prostate-specific antigen (PSA) test or digital rectal exam (DRE) was considered to have 
received prostate cancer screening.
Analyses of chronic disease impacts compared individuals with 1, 2–3, and 4 or more of 16 
selected chronic diseases to those with none of these diseases. The selected chronic diseases 
included: Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/
AIDS), chronic obstructive pulmonary disease (COPD), renal failure, arthritis, hypertension, 
congestive heart failure, hepatitis, obesity, asthma, coronary heart disease (CHD), 
degenerative diseases of the central nervous system (CNS), depression, diabetes, mental 
retardation, organic psychoses, and stroke. Individuals were identified as having diseases 
based on claims with an International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM) diagnosis code (http://www.cdc.gov/nchs/icd/icd9cm.htm). 
Individuals with at least one inpatient or long-term care claim with an ICD-9-CM diagnosis 
were classified as having that disease. For other services (physician, hospital outpatient, 
clinic, laboratory, radiology, therapies, and home health), in order to avoid “rule out” claims, 
individual were required to have at least two claims on different dates with the diagnosis 
code.
Analyses of the impact of LTC residence on cancer screenings compared individuals with 0 
days vs. those with 120 more or days of residence in a Medicaid-covered facility during an 
observation period. Individuals with 1–120 days of residence in a Medicaid-covered facility 
were excluded from the LTC study population because their service use is less likely to be 
influenced by LTC facility residence. The count of long-term care days was obtained from 
Medicaid LTC facility claims, including nursing facilities, intermediate care facilities for the 
mentally retarded, and mental hospitals for the aged. In each state, at least 85% of the long-
term care facility claims were associated with nursing facilities.
Analytic Methods
Analyses used multivariate logistic regressions, controlling for age (expressed as a 
continuous variable), age squared, sex, race/ethnicity (Black, Hispanic, and other, with 
White omitted), metropolitan residence status, and state fixed effects for each observation 
period. Individuals with chronic diseases may see a doctor more frequently, which could 
increase the likelihood of receiving cancer screening tests. Chronic disease regressions 
therefore also controlled for the number of office visits (0, 1–3, 4–6, 7–9, 10 or more) 
identified by CPT codes 99201–99215. Office visits on the same date as a cancer screening 
test were not included in the count. The LTC regressions also controlled for number of 
chronic diseases.
Halpern et al. Page 4
J Anal Oncol. Author manuscript; available in PMC 2018 March 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Analyses were weighted by months of fee-for-service enrollment during the 12-month 
period. Standard errors in analyses of the Medicaid-only population were adjusted to 
account for multiple observations for the same individual. Analyses were conducted using 
SAS version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Table 1 presents characteristics for Medicaid coverage-only enrollees (i.e., non-dual 
enrollees) while Table 2 presents characteristics for dual Medicare/Medicaid enrollees. 
Among the Medicaid-only population, LTC residents were only 2.1% of the total study 
population, while LTC residents were almost 15% of the dually-eligible enrollees. The 
majority of Medicaid-only enrollees (61.8%) had no chronic conditions; only 3.5% had four 
or more chronic conditions. In contrast, 21.2% of Medicare-Medicaid enrollees had no 
chronic conditions while a similar proportion (20.1%) had four or more conditions.
Among Medicaid-only enrollees, LTC residents and those with more chronic conditions 
were older and more likely to be male, although a majority of enrollees in all groups were 
female. Whites constituted approximately 40% of the non-LTC and chronic disease enrollees 
but more than half of the LTC enrollees. Table 1 also presents the proportion of Medicaid 
only enrollees in each LTC or chronic condition group who were eligible for the indicated 
cancer screening based on age and sex. Proportions ranged from approximately 7% of 
enrollees with no chronic conditions being eligible for prostate cancer screening to 93% of 
the same group (enrollees with no chronic conditions) being eligible for Pap tests. Among 
enrollees with chronic conditions, all chronic conditions except HIV were associated with 
increased likelihood of receiving any CRC screening. Enrollees with arthritis, asthma, CHD, 
depression, diabetes, hypertension, mental retardation, or obesity were more likely to receive 
mammograms. Enrollees with depression or HIV were more likely to receive Pap tests, 
while enrollees with arthritis, CHD, COPD, depression, diabetes, hypertension, or mental 
retardation were more likely to receive PSA tests (data not shown). All difference between 
LTC vs. non-LTC enrollees and for enrollees with zero versus 1, 2–3, or 4 or more chronic 
conditions are statistically significant at p<0.0001.
Similar relationships between demographic characteristics and LTC status or number of 
chronic conditions were observed among the dual Medicaid-Medicare enrollees (Table 2). 
Among dually-eligible individuals, LTC residents and those with more chronic conditions 
were older. The proportion of White enrollees among the dual population was greater than 
that among the Medicaid-only population, with more than three-quarters of LTC enrollees 
being White. The proportion of dually-eligible enrollees eligible for each screening test 
(based on age and sex) was greatest for CRC screening and least for prostate cancer 
screening. Among enrollees with chronic conditions, all chronic conditions except HIV, 
degenerative diseases of the CNS, organic psychoses, or stroke were associated with 
increased likelihood of receiving any CRC screening. Enrollees with asthma, HIV, or mental 
retardation were more likely to receive mammograms. Enrollees with asthma, depression, 
HIV, mental retardation, or obesity were more likely to receive Pap tests, while enrollees 
with arthritis, hypertension, or mental retardation were more likely to receive PSA tests (data 
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not shown). All differences between LTC vs. non-LTC enrollees and for enrollees with zero 
versus 1, 2–3, or 4 or more chronic conditions are statistically significant at p<0.0001.
Figures 1 and 2 present results from multivariate logistic regression analyses of the rates of 
cancer screening tests among the study populations. Odds ratios and 95% confidence 
intervals are presented; as noted in the Methods sections, the odds ratios indicate the 
likelihood of receiving each screening test during an observation period of up to 12 months, 
not of receiving guideline-concordant cancer screenings. Odds ratios are determined with 
non-LTC residents as the reference group for the LTC study population and enrollees with 
zero chronic conditions as the reference group for the chronic condition study population.
As illustrated in Figure 1, Medicaid-only LTC residents were significantly less likely to 
receive mammography or Pap tests than were non-LTC residents after controlling for the 
specified patient characteristics; no significant difference was observed for CRC and 
prostate cancer screening. Those with chronic conditions were significantly more likely to 
receive CRC screening, mammography, or prostate cancer screening. While the likelihood of 
receiving Pap tests was significantly (although only slightly) greater among Medicaid-only 
enrollees with one (vs. zero) chronic condition, Pap test rates were significantly lower 
among Medicaid-only enrollees with two or more chronic conditions.
Figure 2 presents the corresponding odds ratios for dual Medicare-Medicaid enrollees. 
Among this population, LTC residents were significantly less likely to receive all four cancer 
screenings compared with non-LTC residents. This reduction was especially large for 
mammography: dual LTC residents in this group had only one-third the likelihood of 
receiving mammography as did non-LTC residents. Similar to results for Medicaid-only 
enrollees, the likelihoods of CRC and prostate cancer screening among dual Medicaid-
Medicare enrollees with chronic conditions were increased compared with those without 
chronic conditions. However, while dually-eligible enrollees with one chronic condition 
were also significantly more likely to receive mammography, those with two or more 
chronic conditions were significantly less likely to receive mammography. Similarly, dual 
enrollees with one chronic condition were more likely than those without chronic conditions 
to receive Pap tests, but those with 4 or more chronic conditions were significantly less 
likely to receive Pap tests.
DISCUSSION
This study assessed the association of LTC residency and multiple chronic conditions with 
the likelihood of receiving recommended cancer screening services among Medicaid 
enrollees. Our results indicated that all examined cancer screening tests are less likely to be 
performed among dual Medicaid-Medicare enrollees residing in long-term care facilities, 
while mammography and Pap tests are less likely to be performed among Medicaid-only 
enrollees in LTC facilities. Approximately 1.8 million individuals in the U.S. reside in 
nursing homes and the total number of nursing facility residents may increase in the future 
due to aging of the U.S. population. Ensuring appropriate cancer screening services among 
this large population presents additional challenges, due to their limited interactions with 
physicians and higher risk of developing certain types of cancer. For example, in a small 
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study (95 individuals) of women age 75 and older residing in a skilled nursing facility, 
almost half (45%) of the performed mammograms involved abnormal findings that required 
clinical follow-up [10].
While underuse of screening may increase the risk of delayed or missed diagnoses, it is also 
important to consider the observed differences in cancer screening rates among LTC 
residents in the context of recommendations to appropriately discontinue screening. Welch 
& Black estimated that approximately 25% of breast cancers identified by mammography 
and 60% of prostate cancers detected by PSA may reflect overdiagnosis [1]. In addition, 
certain guidelines indicate that cancer screening may not always be indicated for individuals 
with short life expectancy. Previous reports have indicated that a substantial proportion of 
nursing home residents have relatively short life expectancies [11,12]. As such, lower rates 
of screening among certain LTC residents may be appropriate. Unfortunately, Medicaid 
claims data lack information on severity of comorbidities and life expectancy, so we were 
unable to control for these factors in our analyses.
However, not all individuals in LTC facilities have short life expectancies that might suggest 
appropriate discontinuation of cancer screening; Spillman & Lubitz estimated that among 
community residents age 65 and older who enter a nursing home, approximately 20% will 
spend five years or longer there [13]. In addition, Medicaid-enrolled nursing home residents 
may not receive appropriate cancer screening that could diagnose cancers at early stages. 
Bradley et al. reported that the majority (62%) of cancers among a Medicaid nursing home 
population were diagnosed with a SEER summary stage of distant or invasive but unknown 
[14]. A late stage or unstaged cancer diagnosis limits options for potentially curative 
treatment, particularly among those LTC residents who may have had longer life 
expectancies.
Further, appropriate cancer screening may lead to earlier diagnosis and therefore earlier 
initiation of needed supportive or palliative care for LTC residents with cancer [14]. Clement 
et al., examining Medicaid claims and tumor registry data for nursing home residents 
diagnosed with cancer after admission, found that 25% of these individuals were diagnosed 
at death or within one month of death [15]. With this late diagnosis, there was reduced 
opportunity for provision of palliative care. As early initiation of supportive/palliative care 
has been shown to decrease pain and improve quality of life among individuals diagnosed 
with cancer [16,17], Medicaid enrollees in long term care setting would likely benefit from 
earlier diagnosis.
Among the study population, the presence of chronic medical conditions was associated 
with mixed effects on the likelihood for cancer screening. We had expected that individuals 
with more comorbidities would be less likely to be screened for cancer. Some reports have 
indicated that individuals with severe comorbidities are less likely to receive cancer 
screenings [18,19]; however, other studies have reported mixed associations between 
comorbidities and screening [20–23].
There are a number of limitations associated with this study. Medicaid enrollees tend to have 
lower socioeconomic status than do individuals not enrolled in Medicaid, and include a 
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higher proportion of individuals from racial/ethnic minority groups compared with the 
overall U.S. population. These factors may limit the generalizability of these results beyond 
the Medicaid population. In addition, the relatively short period of enrollment in Medicaid 
for many individuals, particularly non-duals, makes assessment of longitudinal patterns of 
medical care resource utilization (including cancer screening) difficult [24]. Our rates for 
certain cancer screening tests therefore almost certainly underestimate the actual proportion 
of enrollees receiving appropriate screening. However, this underestimate is likely to apply 
to all patient groups (i.e., LTC vs. non-LTC residents and individuals with varying numbers 
of chronic conditions) in a similar manner, as all screening rates are based on 12-month 
observation periods. Also, these analyses of receipt of a screening test during a 12-month 
period do not indicate whether guidelines for cancer screening were met, since guideline 
periods varied by screening test.
We were also unable to differentiate between cancer screening tests and similar procedures 
performed for other purposes (e.g., colonoscopies performed for evaluation of individuals 
with ulcerative colitis or similar conditions). However, since tests or procedures performed 
for the diagnosis of non-cancer conditions or for treatment purposes would likely have 
identified neoplastic lesions even if that was not their main purpose, inclusion of such tests 
is appropriate. It is also possible that patients received screening services not captured by the 
claims data. However, it is unlikely that a substantial proportion of Medicaid enrollees 
received cancer screening that was not covered by their state’s Medicaid (or in the case of 
dual enrollees, Medicare and Medicaid) program. We are also unable to determine whether 
missed cancer screening opportunities resulted in delayed or missed cancer diagnoses. 
Finally, the data used for this study are also at least eight years old; screening patterns may 
have changed in subsequent years.
Despite these limitations, this study provides important information related to cancer 
screening among a low socioeconomic status, underserved population. Given the 
significantly lower cancer screening rates among LTC residents, new interventions targeting 
patients, physicians, and LTC facility administrators are needed to highlight the importance 
of such screenings for appropriate individuals. Future efforts in these areas could involve 
both provider-level interventions, including training for health professionals in LTC 
environments on the importance of screenings among appropriate residents, and system-
level interventions, such as reminders for screenings occurring automatically in electronic 
medical records and modification or expansion of mammography and colonoscopy facilities 
to facilitate screenings for LTC residents.
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Figure 1. Logistic Regression Analysis of Rates of Cancer Screening Tests for Medicaid Only 
(Non-Dual) Enrollees (Odds Ratios and Upper 95% Confidence Intervals)
Regression analyses controlled for age, age squared, sex, race/ethnicity, urban-rural 
residence status, state, number of chronic conditions (LTC study regressions only) and 
number of outpatient physician visits (chronic condition study regressions only). LTC 
regressions utilized non-LTC residents as the reference group; chronic condition regressions 
utilized individuals with zero chronic conditions as the reference group. All odds ratios are 
statistically significant at p<0.0001 except for CRC screening among LTC residents (not 
significant), Pap test among LTC residents (p=0.0006), prostate cancer screening among 
LTC residents (not significant) and mammography among enrollees with four or more 
chronic conditions (p=0.01).
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Figure 2. Logistic Regression Analysis of Rates of Cancer Screening Tests for Dual Medicare-
Medicaid Enrollees (Odds Ratios and Upper 95% Confidence Intervals)
Regression analyses controlled for age, age squared, sex, race/ethnicity, urban-rural 
residence status, state, number of chronic conditions (LTC study regressions only) and 
number of outpatient physician visits (chronic condition study regressions only). LTC 
regressions utilized non-LTC residents as the reference group; chronic condition regressions 
utilized individuals with zero chronic conditions as the reference group. All odds ratios are 
statistically significant at p<0.0001 except for mammography among enrollees with 2–3 
chronic conditions (p=0.03) and Pap test among enrollees with 2–3 chronic conditions (not 
significant).
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